Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05977088). This is a study registration, not published results. Lead sponsor: Istanbul Medipol University Hospital. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 40 participants (ACTUAL). Conditions: Alzheimer Disease. Interventions: DEVICE: Repetetive Transcranial Magnetic Stimulation. Primary outcome measures: The Mini Mental State Examination , Changes Before Treatment and 1 month after treatment; Neuropsychiatric Inventory , Changes Before Treatment and 1 month after treatment; Alzheimer's Disease Assessment Scale , Changes Before Treatment and 1 month after treatment; ADSL , Changes Before Treatment and 1 month after treatment; Geriatric Depression Scale , Changes Before Treatment and 1 month after treatment. Brief summary: Since pharmacological methods are insufficient in the treatment processes of Alzheimer's disease, non-pharmacological methods such as Transcranial Magnetic Stimulation (TMS) have started to be tried as a treatment option as in other neurological and psychiatric diseases. Repeated (rTMS) offers a potential treatment pathway for neurological and psychiatric illnesses. rTMS benefit rate may vary depending on many factors such as the region where it is applied, the progression and the disease degree. The possible effects of TMS on Alzheimer's pathophysiology and modification of disease process (neuroprotective, anti-inflammatory and antioxidant) will also be revealed through blood samples taken from patients before and after treatment. These approaches also constitute the original value of our study.